These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37954554)

  • 1. Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation.
    Klaas JE; Bui V; Maierhofer N; Schworm B; Maier M; Priglinger SG; Siedlecki J
    Front Med (Lausanne); 2023; 10():1295633. PubMed ID: 37954554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review.
    Uzzan J; Mapani A; Cox O; Bagijn M; Saffar I
    Ophthalmol Ther; 2024 Sep; 13(9):2445-2465. PubMed ID: 39066961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient Vision Loss Associated with Prefilled Aflibercept Syringes: A Case Series and Analysis of Injection Force.
    Lee DJ; Scruggs BA; Sánchez E; Thomas M; Faridi A
    Ophthalmol Sci; 2022 Jun; 2(2):. PubMed ID: 36211641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals.
    Antoszyk AN; Baker C; Calzada J; Cummings H; So J; Quezada-Ruiz C; Haskova Z
    PDA J Pharm Sci Technol; 2018; 72(4):411-419. PubMed ID: 29853609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Prefilled vs Vial-Drawn Syringes on Sustained Increases in Intraocular Pressure in Patients Treated With Aflibercept.
    Russell MW; Chalasani M; Rana N; Muste JC; Rachitskaya AV; Talcott KE; Singh RP; Sharma S
    J Vitreoretin Dis; 2023; 7(6):498-503. PubMed ID: 37974923
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease.
    Hsia NY; Lin CJ; Lai CT; Bair H; Chang CH; Lin JM; Tsai YY
    Case Rep Ophthalmol Med; 2021; 2021():8887362. PubMed ID: 33628552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
    Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe.
    Guest JM; Malbin B; Abrams G; Parendo A; Das S; Okeagu C; Ross BX; Kumar A; Lin X
    Int J Retina Vitreous; 2022 Apr; 8(1):27. PubMed ID: 35382900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impurities in Drug Vials Intended for Intravitreal Medication.
    Pohl L; Strudel L; Dimopoulos S; Ziemssen F
    Case Rep Ophthalmol Med; 2020; 2020():8824585. PubMed ID: 34055435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022.
    Schmidt-Ott U; Fitzpatrick S; Hasanbasic Z; Leal S; Morgan-Warren P; Zhang X; Johnson KT
    Clin Ophthalmol; 2023; 17():385-390. PubMed ID: 36726365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.
    Hykin P; Prevost AT; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Hounsome B; Yang Y; Harding SP; Lotery A; Chakravarthy U; Sivaprasad S;
    JAMA Ophthalmol; 2019 Nov; 137(11):1256-1264. PubMed ID: 31465100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Prefilled Syringes and Masking on Postintravitreal Injection Endophthalmitis.
    Louis AM; Ali AM; Patel SB; Fan KC; Rahman EZ; Pearce WA; Trejo Corona S; Villanueva Boone C; Yu HJ; Wykoff CC
    J Vitreoretin Dis; 2023; 7(5):382-388. PubMed ID: 37706081
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V
    J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deformation of Aflibercept and Ranibizumab Syringes Causes Variation in Intravitreal Injection Volume and Risks Retinal Tear Formation.
    Raevis JJ; Lemire CA; Ramsey DJ; Riccobono J; Gonzalez E
    Ophthalmol Sci; 2022 Dec; 2(4):100202. PubMed ID: 36531591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study.
    Kishishita S; Sakanishi Y; Morita S; Matsuzawa M; Usui-Ouchi A; Ebihara N
    BMC Ophthalmol; 2022 Nov; 22(1):458. PubMed ID: 36447155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
    JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.